| Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial TS Maughan, RA Adams, CG Smith, AM Meade, MT Seymour, RH Wilson, ... The Lancet 377 (9783), 2103-2114, 2011 | 1289 | 2011 |
| Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies S Venderbosch, ID Nagtegaal, TS Maughan, CG Smith, JP Cheadle, ... Clinical Cancer Research 20 (20), 5322-5330, 2014 | 810 | 2014 |
| Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label … RD James, R Glynne-Jones, HM Meadows, D Cunningham, AS Myint, ... The lancet oncology 14 (6), 516-524, 2013 | 766 | 2013 |
| Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial MT Seymour, TS Maughan, JA Ledermann, C Topham, R James, ... The Lancet 370 (9582), 143-152, 2007 | 740 | 2007 |
| Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the … J Franko, Q Shi, JP Meyers, TS Maughan, RA Adams, MT Seymour, ... The Lancet Oncology 17 (12), 1709-1719, 2016 | 576 | 2016 |
| Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial J Primrose, S Falk, M Finch-Jones, J Valle, D O'Reilly, A Siriwardena, ... The lancet oncology 15 (6), 601-611, 2014 | 508 | 2014 |
| Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial MT Seymour, LC Thompson, HS Wasan, G Middleton, AE Brewster, ... The Lancet 377 (9779), 1749-1759, 2011 | 491 | 2011 |
| Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified … MT Seymour, SR Brown, G Middleton, T Maughan, S Richman, S Gwyther, ... The lancet oncology 14 (8), 749-759, 2013 | 455 | 2013 |
| Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial T Crosby, CN Hurt, S Falk, S Gollins, S Mukherjee, J Staffurth, R Ray, ... The lancet oncology 14 (7), 627-637, 2013 | 440 | 2013 |
| Meta-analysis of three genome-wide association studies identifies susceptibility loci for colorectal cancer at 1q41, 3q26. 2, 12q13. 13 and 20q13. 33 RS Houlston, J Cheadle, SE Dobbins, A Tenesa, AM Jones, K Howarth, ... Nature genetics 42 (11), 973-977, 2010 | 425 | 2010 |
| Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial S Mukherjee, CN Hurt, J Bridgewater, S Falk, S Cummins, H Wasan, ... The lancet oncology 14 (4), 317-326, 2013 | 413 | 2013 |
| Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial SR Bramhall, MT Hallissey, J Whiting, J Scholefield, G Tierney, RC Stuart, ... British journal of cancer 86 (12), 1864-1870, 2002 | 371 | 2002 |
| Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase … RA Adams, AM Meade, MT Seymour, RH Wilson, A Madi, D Fisher, ... The lancet oncology 12 (7), 642-653, 2011 | 362 | 2011 |
| Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized … G Folprecht, MT Seymour, L Saltz, JY Douillard, H Hecker, RJ Stephens, ... Journal of Clinical Oncology 26 (9), 1443-1451, 2008 | 291 | 2008 |
| Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial TS Maughan, RD James, DJ Kerr, JA Ledermann, MT Seymour, ... The Lancet 361 (9356), 457-464, 2003 | 258 | 2003 |
| Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed MJ Keating, B Cazin, S Coutre, R Birhiray, T Kovacsovics, W Langer, ... Journal of Clinical Oncology 20 (1), 205-213, 2002 | 244 | 2002 |
| Association analyses identify 31 new risk loci for colorectal cancer susceptibility PJ Law, M Timofeeva, C Fernandez-Rozadilla, P Broderick, J Studd, ... Nature communications 10 (1), 2154, 2019 | 231 | 2019 |
| Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled … JA Bridgewater, SA Pugh, T Maishman, Z Eminton, J Mellor, A Whitehead, ... The lancet oncology 21 (3), 398-411, 2020 | 208 | 2020 |
| Image-based consensus molecular subtype (imCMS) classification of colorectal cancer using deep learning K Sirinukunwattana, E Domingo, SD Richman, KL Redmond, A Blake, ... Gut 70 (3), 544-554, 2021 | 199 | 2021 |
| Investigating the poor outcomes ofBRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials JF Seligmann, D Fisher, CG Smith, SD Richman, F Elliott, S Brown, ... Annals of Oncology 28 (3), 562-568, 2017 | 186 | 2017 |
